Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast plus doxycycline for mild to moderate cutaneous pemphigoid
NL-OMON49116Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of apremilast and doxycycline in Bullous Pemphigoid (BP) and pemphigoid, sponsored by University Medical Center Groningen. Started Jul 2019; status: active, not recruiting.
02
Drugs
apremilastdoxycycline
03
Conditions
Bullous Pemphigoid (BP)pemphigoid
Beyond the preview
Go deeper on NL-OMON49116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49116.